ClinicalTrials.Veeva

Menu

Hip Fracture and Muscle Resilience (HIPRESM)

A

Assistance Publique - Hôpitaux de Paris

Status

Completed

Conditions

Hip Fracture, Post Surgery Recovery, Muscle Resilience

Treatments

Device: High definition surface electromyography (HD-sEMG)

Study type

Observational

Funder types

Other

Identifiers

NCT04167020
2019-A00770-57 (Other Identifier)
APHP180486

Details and patient eligibility

About

The aging of the population is a major public health problem, particularly with regard to the quality of life and the maintenance of autonomy.

The fracture of the upper end of the femur (EFSF) is a pathology:

  • Frequent, affecting the elderly: in France, 80,000 patients / year, 83% aged ≥ 75 years (DREES, 2011),
  • severe, on mortality and autonomy: 40% will not recover their walking capacity earlier than 6 months, 13% of patients > 85 years old walk unaided at 4 months and 11% of patients will be newly admitted to an institution in 6 months after the fracture (UPOG / PSL data).
  • and costly: costs related to acute care (excluding prostheses and osteosynthesis equipment), are estimated at € 475 million for health insurance in France.

Currently, despite optimized orthogeriatric management, it is difficult to predict how the individual will respond / recover from acute stress related to the EFSF. Physical resilience is an emerging concept in medicine that defines the dynamic ability of a subject to resist or recover from functional decline as a result of stress or disruption. In this context, developing new approaches to assessing resilience is important, to take into account this resilience specific to each patient in order to develop a personalized functional rehabilitation strategy. The objective of the HIPRESM study is to be able to identify, in elderly patients after an EFSF intervention, the muscular signature associated with good functional recovery (= physical resilience). The goal of the investigators is to develop software that will provide this muscle signature by measuring and analyzing parameters from high-definition surface electromyography (HD-sEMG). This technology is innovative, non-invasive and portable, CE marked but not yet used in clinical routine.

Full description

The aging of the population is a major public health problem with its multifactorial impact, quality of life and the maintenance of autonomy.

The upper femoral fracture (UFF) is a common pathology: in France, it concerns nearly 80.000 patients per year, 83% of whom are aged 75 (DREES, 2011).

The UFF is a pathology with serious consequences, on the mortality but also on the functional level, since 40% of the patients will not recover their walking capacity previous to 6 months, only 13% of the patients over 85 years old will walk unaided to 4 months and 11% of patients will be newly admitted to an institution within 6 months of the fracture (UPOG data, 20% for patients with major neurocognitive disorders, 4% for others). In the literature, at least 25% of elderly people will not recover their previous walking ability, especially for transfers, walking and climbing stairs (Alarcon 2011, Arinzon 2010, Visser 2000).

The UFF is an expensive pathology, whose costs related to acute care (excluding prostheses and osteosynthesis equipment), are estimated at € 475 million in health insurance in France.

Currently, despite optimized orthogeriatric management, it is difficult to predict how the individual will respond/recover from acute UFF-related stress. Physical resilience is an emerging concept in medicine, which defines the dynamic ability of a subject to resist or recover from a functional decline due to stress or disruption. In this context, developing new approaches to assess resilience is important, to take into account each patient's specific resilience in order to develop a personalized functional rehabilitation strategy. The objective of the HIPRESM study is to identify, in older patients after a UFF intervention, the muscle signature associated with good functional recovery (= physical resilience). The objective of the investigators is to identify the parameters derived from high definition surface electromyography (HD-sEMG) by developing software that will provide this muscle signature. This technology is innovative, non-invasive and portable, and already CE marked.

Main objective: to identify HD-sEMG parameters, measured during quadriceps extension of the lower limb not affected by surgery, within 7 days post surgery for UFF, associated with functional status without human assistance (SPPB) at day 30.

Main Evaluation Criterion: To investigate the association between the parameters provided by HD-sEMG (32 simultaneous channels; portable device and software, Mobita®) of the rectus femoris and functional status without human assistance measured by the Short Physical Performance Battery (SPPB = walking speed over 4 meters, chair satnds, balance) at 30 days after surgery for FESF.

Secondary objectives: to study the association between parameters from HD-sEMG measured during quadriceps extension of the lower limb not affected by surgery within 7 days post surgery for FESF and :

  1. the walking capacity at D30
  2. the autonomy at D30
  3. the walking speed over 5m at D30
  4. the quality of life on D30
  5. the evolution of HD-sEMG muscle quality at D30
  6. in-hospital mortality and at D30
  7. the time required for rehospitalization
  8. the average length of stay in Follow-up Care and Rehabilitation and in the orthogeriatric stream

Secondary evaluation criteria:

  1. Walking ability without human assistance: autonomous walking, with technical assistance, impossible, at D30
  2. Autonomy measured by the ADL scale at D30
  3. Walking speed over 5 meters at D30
  4. Quality of life assessed by the EQ5D questionnaire at D30
  5. HD-sEMG settings at D30
  6. Death in hospital and at D30
  7. The time required for rehospitalization
  8. The average length of stay in rehabilitation and orthogeriatric care

Enrollment

67 patients

Sex

All

Ages

70+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient ≥ 70 years old
  • Managed by orthogeriatric unit after upper femoral fracture surgery
  • Patient informed of the study and who has not objected to his participation.

Exclusion criteria

  • Patient bedridden before the femoral fracture, with limited autonomy to bed-chair transfers
  • Any other associated fracture
  • Cutaneous allergy with adhesive plaster
  • BMI ≥ 30 kg / m²
  • Cognitive disorders preventing the correct execution of the movement

Trial contacts and locations

4

Loading...

Central trial contact

KIYOKA KINUGAWA, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems